These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 26198339)
1. The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome. de Koning HD; Schalkwijk J; Stoffels M; Jongekrijg J; Jacobs JF; Verwiel E; Koenen HJ; Preijers F; Holzinger D; Joosten I; van der Meer JW; Simon A Arthritis Res Ther; 2015 Jul; 17(1):187. PubMed ID: 26198339 [TBL] [Abstract][Full Text] [Related]
2. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. de Koning HD; Schalkwijk J; van der Ven-Jongekrijg J; Stoffels M; van der Meer JW; Simon A Ann Rheum Dis; 2013 Oct; 72(10):1634-8. PubMed ID: 23087179 [TBL] [Abstract][Full Text] [Related]
3. Mast-cell interleukin-1β, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler's syndrome. de Koning HD; van Vlijmen-Willems IM; Rodijk-Olthuis D; van der Meer JW; Zeeuwen PL; Simon A; Schalkwijk J Br J Dermatol; 2015 Aug; 173(2):448-56. PubMed ID: 25904179 [TBL] [Abstract][Full Text] [Related]
4. Association of CCL2 with systemic inflammation in Schnitzler syndrome. Krause K; Sabat R; Witte-Händel E; Schulze A; Puhl V; Maurer M; Wolk K Br J Dermatol; 2019 Apr; 180(4):859-868. PubMed ID: 30339714 [TBL] [Abstract][Full Text] [Related]
6. A case of Schnitzler's syndrome without monoclonal gammopathy successfully treated with canakinumab. Fujita Y; Asano T; Sakai A; Norikawa N; Yamamoto T; Matsumoto H; Sato S; Temmoku J; Yashiro-Furuya M; Matsuoka N; Watanabe H; Migita K BMC Musculoskelet Disord; 2021 Mar; 22(1):257. PubMed ID: 33685423 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of interleukin-1 blockade in Schnitzler's syndrome without detectable monoclonal gammopathy: a case-based review. Bixio R; Rossini M; Giollo A Clin Rheumatol; 2021 Jul; 40(7):2973-2977. PubMed ID: 33175311 [TBL] [Abstract][Full Text] [Related]
8. A Case of Schnitzler's Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra. Ahn MJ; Yu JE; Jeong J; Sim DW; Koh YI Yonsei Med J; 2018 Jan; 59(1):154-157. PubMed ID: 29214791 [TBL] [Abstract][Full Text] [Related]
9. Schnitzler's Syndrome-Diagnostic Experience, Approaches to Therapy, and Patient Management according to a Multicenter Russian Cohort. Salugina SO; Torgashina AV; Borzova EY; Rameev VV; Gorodetsky VR; Fedorov ES; Muravyova NV Dokl Biochem Biophys; 2024 Aug; 517(1):214-227. PubMed ID: 38861148 [TBL] [Abstract][Full Text] [Related]
10. Skin and Systemic Inflammation in Schnitzler's Syndrome Are Associated With Neutrophil Extracellular Trap Formation. Bonnekoh H; Scheffel J; Wu J; Hoffmann S; Maurer M; Krause K Front Immunol; 2019; 10():546. PubMed ID: 30967871 [TBL] [Abstract][Full Text] [Related]
11. Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome. Gorodetskiy VR; Salugina SO; Fedorov ES Case Rep Rheumatol; 2018; 2018():5416907. PubMed ID: 29850358 [TBL] [Abstract][Full Text] [Related]
12. Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab. Salcedo-Mingoarranz AL; Dorado-Fernández M; García-Martínez S; Collado-Ramos P; Silvestre-Torner N J Dermatolog Treat; 2023 Dec; 34(1):2242705. PubMed ID: 37551725 [TBL] [Abstract][Full Text] [Related]
13. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Simon A; Asli B; Braun-Falco M; De Koning H; Fermand JP; Grattan C; Krause K; Lachmann H; Lenormand C; Martinez-Taboada V; Maurer M; Peters M; Rizzi R; Rongioletti F; Ruzicka T; Schnitzler L; Schubert B; Sibilia J; Lipsker D Allergy; 2013; 68(5):562-8. PubMed ID: 23480774 [TBL] [Abstract][Full Text] [Related]
14. Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease? Migliorini P; Del Corso I; Tommasi C; Boraschi D Eur Cytokine Netw; 2009 Sep; 20(3):108-11. PubMed ID: 19825519 [TBL] [Abstract][Full Text] [Related]
15. Dysfunctional inflammasome in Schnitzler's syndrome. Pizzirani C; Falzoni S; Govoni M; La Corte R; Donadei S; Di Virgilio F; Trotta F; Lo Monaco A Rheumatology (Oxford); 2009 Oct; 48(10):1304-8. PubMed ID: 19696060 [TBL] [Abstract][Full Text] [Related]
18. [Schnitzler's syndrome: a case report and literature review of the response to treatment with anakinra]. Benítez Gutiérrez L; Mellor Pita S; Tutor de Ureta P; Yebra Bango M Med Clin (Barc); 2013 May; 140(9):427-8. PubMed ID: 23177777 [No Abstract] [Full Text] [Related]
19. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Krause K; Weller K; Stefaniak R; Wittkowski H; Altrichter S; Siebenhaar F; Zuberbier T; Maurer M Allergy; 2012 Jul; 67(7):943-50. PubMed ID: 22583335 [TBL] [Abstract][Full Text] [Related]
20. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. de Koning HD; Bodar EJ; Simon A; van der Hilst JC; Netea MG; van der Meer JW Ann Rheum Dis; 2006 Apr; 65(4):542-4. PubMed ID: 16096327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]